Clinical trial
Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)
NCT07561983 is registered in ClinicalTrials.gov with Sichuan Cancer Hospital and Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)
- Lead sponsor
- Sichuan Cancer Hospital and Research Institute
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- May 1, 2026
- Completion date
- December 31, 2028
- Enrollment
- 39 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chemoembolization, therapeutic, chemotherapy, conversion therapy, tislelizumab, unresectable stage iii non-small cell lung cancer